Armistice Capital’s Immunocore IMCR Stock Holding History

Armistice Capital’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.8M	Buy	1,188,000 +90,000	+8%	+$2.91M	0.64%	24
2025 Q4	$38.1M	Buy	1,098,000 +274,000	+33%	+$9.67M	0.45%	35
2025 Q3	$29.9M	Buy	824,000 +146,000	+22%	+$4.96M	0.44%	33
2025 Q2	$21.3M	Sell	678,000 -300,000	-31%	-$9.32M	0.37%	44
2025 Q1	$29M	Sell	978,000 -222,000	-19%	-$6.66M	0.43%	46
2024 Q4	$35.4M	Sell	1,200,000 -64,000	-5%	-$2.02M	0.48%	39
2024 Q3	$39.3M	Buy	1,264,000 +288,000	+30%	+$10.5M	0.63%	32
2024 Q2	$33.1M	Buy	976,000 +812,000	+495%	+$41.4M	0.42%	42
2024 Q1	$10.7M	Sell	164,000 -148,000	-47%	-$10.2M	0.14%	98
2023 Q4	$21.3M	Sell	312,000 -88,000	-22%	-$4.57M	0.29%	58
2023 Q3	$20.8M	Sell	400,000 -28,000	-7%	-$1.66M	0.32%	55
2023 Q2	$25.7M	Buy	428,000 +50,000	+13%	+$2.85M	0.37%	52
2023 Q1	$18.7M	Buy	378,000 +42,000	+13%	+$2.36M	0.27%	68
2022 Q4	$19.2M	Buy	336,000 +20,000	+6%	+$1.13M	0.33%	58
2022 Q3	$14.8M	Buy	316,000 +48,000	+18%	+$2.29M	0.26%	66
2022 Q2	$10K	Buy	268,000 +88,000	+49%	+$2.86M	0.17%	79
2022 Q1	$5.38M	Buy	+180,000	New	+$4.54M	0.1%	84

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Armistice Capital's IMCR Position: Q1 2026 in Review

Armistice Capital increased its Immunocore (IMCR) stake by 8.2% in Q1 2026, buying an estimated $2.91M and bringing the position to 1,188,000 shares worth $35.8M. The position accounts for 0.64% of the portfolio, ranked #24.

Armistice Capital first reported a position in IMCR in Q1 2022 and has held it in 17 quarters since. The position peaked at $39.3M in Q3 2024. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

Armistice Capital held 1,188,000 shares of Immunocore worth $35.8M as of Q1 2026.
Armistice Capital bought 90,000 Immunocore shares in Q1 2026, an estimated $2.91M.
Immunocore made up 0.64% of Armistice Capital's portfolio in Q1 2026, its #24 holding.
Armistice Capital first reported a position in Immunocore in Q1 2022 and has held it in 17 quarters since.
Armistice Capital's Immunocore position peaked at $39.3M in Q3 2024.
142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.